biostudies-literatureUnknown42(5)Ziegler DA<h4>Background</h4>The abscopal effect (AbE) refers to the regression of non-irradiated tumors following localized radiotherapy (RT), suggesting a systemic immune-mediated response. The combination of RT with immunotherapy (IO) has been proposed to enhance the AbE by overcoming RT-induced immunosuppressive mechanisms, but robust evidence, specifically in non-small cell lung cancer (NSCLC), is lacking. This study aimed to determine the prevalence of the AbE and its association with progression-free survival (PFS) and overall survival (OS) in metastatic lung cancer patients receiving RT and IO.<h4>Materials and methods</h4>We analyzed consecutive metastatic lung cancer patients who received IO at a certified lung cancer center in Germany between 2009 and 2021. Inclusion required RT to at leaClinical & experimental metastasis56https://www.ebi.ac.uk/biostudies/studies/S-EPMC12474601biostudies-literatureThe abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.PMC12474601Donath SFischer LARieken SAmbold MSchirmer MAGuhlich MDroge LHKieslich BEl Shafie RBensberg Jvon Diest LAvon Hammerstein-Equord ALeu MAndreas SBraulke FRittmeyer AZiegler DAZiegler SfalseThe abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.<h4>Background</h4>The abscopal effect (AbE) refers to the regression of non-irradiated tumors following localized radiotherapy (RT), suggesting a systemic immune-mediated response. The combination of RT with immunotherapy (IO) has been proposed to enhance the AbE by overcoming RT-induced immunosuppressive mechanisms, but robust evidence, specifically in non-small cell lung cancer (NSCLC), is lacking. This study aimed to determine the prevalence of the AbE and its association with progression-free survival (PFS) and overall survival (OS) in metastatic lung cancer patients receiving RT and IO.<h4>Materials and methods</h4>We analyzed consecutive metastatic lung cancer patients who received IO at a certified lung cancer center in Germany between 2009 and 2021. Inclusion required RT to at lea2025-01-01T00:00:00Z2025 Sep2026-06-04T07:54:17.171Z2026-05-07T03:08:46.292ZS-EPMC124746014100385110.1007/s10585-025-10375-w